Literature DB >> 2724412

The palindromic LTR-LTR junction of Moloney murine leukemia virus is not an efficient substrate for proviral integration.

L I Lobel1, J E Murphy, S P Goff.   

Abstract

We generated viral constructs to test the hypothesis that the major substrate on retroviral DNA that is utilized for proviral DNA integration is the palindromic sequence, termed the LTR-LTR junction, normally present in circular molecules formed by joining the two termini of linear proviral DNA. Recombinant viral genomes were built which carried a selectable marker and an extra copy of the LTR-LTR junction from a cloned circular provirus. The junction sequence in each case was positioned such that its use during integration would lead to an easily detected, aberrantly integrated proviral DNA. Analysis of DNA from cells infected with the virus constructs showed that the introduced junction sequence is used at least 1,000-fold less efficiently than the natural sequences at the ends of the genome. This suggests that a linear or more exotic DNA intermediate is most likely the true precursor for the integration reaction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2724412      PMCID: PMC250744     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Transformation of mammalian cells with genes from procaryotes and eucaryotes.

Authors:  M Wigler; R Sweet; G K Sim; B Wold; A Pellicer; E Lacy; T Maniatis; S Silverstein; R Axel
Journal:  Cell       Date:  1979-04       Impact factor: 41.582

2.  A 32,000-dalton nucleic acid-binding protein from avian retravirus cores possesses DNA endonuclease activity.

Authors:  D P Grandgenett; A C Vora; R D Schiff
Journal:  Virology       Date:  1978-08       Impact factor: 3.616

3.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

4.  Virus-specific DNA in the cytoplasm of avian sarcoma virus-infected cells is a precursor to covalently closed circular viral DNA in the nucleus.

Authors:  P R Shank; H E Varmus
Journal:  J Virol       Date:  1978-01       Impact factor: 5.103

5.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

6.  Mapping unintegrated avian sarcoma virus DNA: termini of linear DNA bear 300 nucleotides present once or twice in two species of circular DNA.

Authors:  P R Shank; S H Hughes; H J Kung; J E Majors; N Quintrell; R V Guntaka; J M Bishop; H E Varmus
Journal:  Cell       Date:  1978-12       Impact factor: 41.582

7.  Proviruses of avian sarcoma virus are terminally redundant, co-extensive with unintegrated linear DNA and integrated at many sites.

Authors:  S H Hughes; P R Shank; D H Spector; H J Kung; J M Bishop; H E Varmus; P K Vogt; M L Breitman
Journal:  Cell       Date:  1978-12       Impact factor: 41.582

8.  Restriction endonuclease cleavage of linear and closed circular murine leukemia viral DNAs: discovery of a smaller circular form.

Authors:  F K Yoshimura; R A Weinberg
Journal:  Cell       Date:  1979-02       Impact factor: 41.582

9.  Endonuclease activity of purified RNA-directed DNA polymerase from avian myeloblastosis virus.

Authors:  M Golomb; D P Grandgenett
Journal:  J Biol Chem       Date:  1979-03-10       Impact factor: 5.157

10.  Retroviral DNA integration: structure of an integration intermediate.

Authors:  T Fujiwara; K Mizuuchi
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

View more
  38 in total

Review 1.  Retroviral DNA integration.

Authors:  P Hindmarsh; J Leis
Journal:  Microbiol Mol Biol Rev       Date:  1999-12       Impact factor: 11.056

2.  Somatic cell mutants resistant to retrovirus replication: intracellular blocks during the early stages of infection.

Authors:  G Gao; S P Goff
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

3.  Removal of 3'-OH-terminal nucleotides from blunt-ended long terminal repeat termini by the avian retrovirus integration protein.

Authors:  A C Vora; M L Fitzgerald; D P Grandgenett
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

4.  The sequence of human immunodeficiency virus type 2 circle junction suggests that integration protein cleaves the ends of linear DNA asymmetrically.

Authors:  J M Whitcomb; S H Hughes
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

5.  Large-scale conformational dynamics of the HIV-1 integrase core domain and its catalytic loop mutants.

Authors:  Matthew C Lee; Jinxia Deng; James M Briggs; Yong Duan
Journal:  Biophys J       Date:  2005-02-24       Impact factor: 4.033

Review 6.  Nucleocapsid protein function in early infection processes.

Authors:  James A Thomas; Robert J Gorelick
Journal:  Virus Res       Date:  2008-02-14       Impact factor: 3.303

7.  Carboxyl-terminal determinants of Abelson protein important for lymphoma induction.

Authors:  K Parmar; R C Huebner; N Rosenberg
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

8.  Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA.

Authors:  F D Bushman; R Craigie
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

9.  Both substrate and target oligonucleotide sequences affect in vitro integration mediated by human immunodeficiency virus type 1 integrase protein produced in Saccharomyces cerevisiae.

Authors:  A D Leavitt; R B Rose; H E Varmus
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Reduced nuclear import of human immunodeficiency virus type 1 preintegration complexes in the presence of a prototypic nuclear targeting signal.

Authors:  J Gulizia; M P Dempsey; N Sharova; M I Bukrinsky; L Spitz; D Goldfarb; M Stevenson
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.